ストックスクリーナーアプリを入手
0.00
100.00%
-0.0941
前日終値:
$0.0941
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$5.67M
収益：
$7.10M
当期純損益:
$-31.59M
株価収益率:
0.00
EPS:
-2.61
ネットキャッシュフロー:
$-26.75M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$2.13
Palatin Technologies Inc. Stock (PTN) Company Profile
名前
Palatin Technologies Inc.
セクター
電話
609-495-2200
住所
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
PTN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTN
Palatin Technologies Inc.
|
0.00 | 5.67M | 7.10M | -31.59M | -26.75M | -2.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 40.54M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ATHE
Alterity Therapeutics Ltd Adr
|
4.75 | 63.36M | 0 | 0 | 0 | 0.00 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
305.31 | 37.83B | 2.35B | -269.70M | -75.39M | -2.09 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2015-06-05 | 繰り返されました | Canaccord Genuity | Buy |
| 2015-01-12 | 繰り返されました | ROTH Capital | Buy |
| 2012-05-23 | 開始されました | Noble Financial | Buy |
| 2007-01-23 | 開始されました | Next Generation | Buy |
Palatin Technologies Inc. (PTN) 最新ニュース
Palatin Technologies (PALI) Teams Up with Key Managers for Inves - GuruFocus
Palatin Technologies (PALI) Teams Up with Key Managers for Investment Strategy | PALI Stock News - GuruFocus
Palatin Technologies, Inc. (AMEX:PTN) Q3 2025 Earnings Call Transcript - MSN
Palatin Technologies (NYSE:PTN) Coverage Initiated by Analysts at StockNews.com - Defense World
Moderate Dry Eye Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | mc2 therapeutics, Palatin Technologies, Novaliq - The Globe and Mail
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update - The Malaysian Reserve
Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Palatin Technologies Reports Q3 2025 Earnings and Updates - TipRanks
Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss By Investing.com - Investing.com Nigeria
Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss - Investing.com Australia
Palatin Technologies Q1 Net Loss Narrows On Lower Expenses - Nasdaq
Palatin Technologies (PTN) to Release Quarterly Earnings on Wednesday - Defense World
Palatin Technologies director Robert DeVeer buys $10,180 in stock By Investing.com - Investing.com Nigeria
Palatin Technologies director Robert DeVeer buys $10,180 in stock - Investing.com
Palatin reveals potential diabetic retinopathy treatments - Investing.com
Palatin reveals potential diabetic retinopathy treatments By Investing.com - Investing.com India
Palatin Unveils Promising Preclinical Data For Diabetic Retinopathy Treatments At ARVO 2025 - Nasdaq
Palatin Technologies Announces Closing of Reduced Public Offerin - GuruFocus
Two new option listings and two option delistings on May 9th - TipRanks
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 - GuruFocus
Palatin expects $11.5M financing to cure NYSE American delisting notice - MSN
Palatin Technologies Announces Closing of Reduced Public Offering - Morningstar
Palatin Technologies Announces Closing of Reduced Public Offering | PTN Stock News - GuruFocus
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 - The Malaysian Reserve
Palatin Technologies (PTN) Reveals Promising Phase 3 Study Results for PL9643 in Dry Eye Disease | PTN Stock News - GuruFocus
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 | PTN Stock News - GuruFocus
PTN Faces Delisting from NYSE American, Shares Transition to OTC Market | PTN Stock News - GuruFocus
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice - Lelezard
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice | PTN Stock News - GuruFocus
Palatin Technologies faces delisting from NYSE American due to low stock price - Investing.com Nigeria
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire
Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs - Investing.com Australia
Palatin Technologies sets terms for $23 million offering By Investing.com - Investing.com South Africa
Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs By Investing.com - Investing.com South Africa
Palatin Prices $11.5 Mln Public Offering - Nasdaq
Palatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug Development - Nasdaq
Palatin (PTN) Aims to Address Delisting Concerns with Public Off - GuruFocus
Palatin Technologies Stock Trading Halted Pending Material Announcement - marketscreener.com
Palatin Expects $11.5 Million Financing to Cure NYSE American De - GuruFocus
Palatin Expects $11.5 Million Financing - citybiz
Palatin Technologies Announces Pricing Of Up To $23 Million Public Offering - marketscreener.com
Palatin Technologies Announces Pricing of up to $23 Million Public Offering - GuruFocus
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice - StreetInsider
Palatin Technologies Inc. (PTN) 財務データ
収益
当期純利益
現金流量
EPS
2.60%
3.89%
大文字化:
|
ボリューム (24 時間):